Skip to content
    GILD
    Earnings call· Dec 2024(Q4 FY24)

    GILEAD SCIENCES, INC. GILD

    Feb 11, 2025 Source

    Executive summary

    Gilead Q4 FY24 — Strong Base Business Growth and Pipeline Advancement

    Gilead delivered strong Q4 and full-year results, driven by robust demand in HIV, oncology, and liver disease, exceeding revenue guidance. The company is advancing a diverse pipeline, particularly in HIV prevention with lenacapavir and oncology with Trodelvy and cell therapies, while navigating near-term headwinds from Medicare Part D reform and FX. Management aims to maintain expense discipline and leverage its model for continued bottom-line growth.

    Highlights

    5
    • Total product sales, excluding Veklury, increased 8% year-over-year to $26.8 billion for FY24, exceeding the 5% to 6% guidance range.

    • Full year HIV sales grew 8% in 2024 to $19.6 billion, significantly ahead of the 5% expectation.

    • Biktarvy sales grew 13% in FY24, maintaining over 50% U.S. market share.

    • Livdelzi sales were approximately $30 million in its first full commercial quarter, exceeding expectations.

    • Oncology sales increased 12% year-over-year to $3.3 billion for FY24.

    Concerns

    4
    • Medicare Part D reform is expected to impact 2025 revenue by approximately $1.1 billion, with almost $900 million in HIV.

    • Veklury fourth quarter sales were $337 million, down 53% year-over-year due to lower COVID-19 hospitalizations.

    • Cell therapy sales were flat sequentially and up 5% year-over-year in Q4, reflecting competitive dynamics and slower-than-targeted uptake.

    • The 2025 guidance reflects a $250 million headwind from FX.

    Guidance & targets

    14
    CategoryTargetConfidence
    Full-year 2025 Total Product Sales
    $28.2B-$28.6B
    high materiality
    High
    Full-year 2025 Total Product Sales (excluding Veklury)
    $26.8B-$27.2B
    high materiality
    High
    Full-year 2025 Veklury Sales
    ~$1.4B
    medium materiality
    Medium
    Full-year 2025 Product Gross Margin
    85%-86%
    medium materiality
    High
    Full-year 2025 R&D Expense
    roughly flat from 2024
    medium materiality
    High
    Full-year 2025 Acquired IPR&D
    ~$400M
    medium materiality
    High
    Full-year 2025 SG&A Expense
    decline by a high single-digit percentage
    medium materiality
    High
    Full-year 2025 Operating Income
    $12.7B-$13.2B
    high materiality
    High
    Full-year 2025 Effective Tax Rate
    ~19%
    medium materiality
    High
    Full-year 2025 Non-GAAP Diluted EPS
    $7.70-$8.10
    high materiality
    High
    Full-year 2025 GAAP Diluted EPS
    $5.95-$6.35
    high materiality
    High
    Q1 2025 HIV Revenue
    decline in the mid-teen percentage range
    medium materiality
    High
    Lenacapavir for PrEP Launch
    mid-year
    high materiality
    High
    Quarterly Cash Dividend Increase
    2.6%
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    HIV
    Driven by demand, higher average realized price, and favorable inventory dynamics. Sequentially, sales were up 7% reflecting typical seasonal inventory dynamics and higher demand, partially offset by lower average realized price. Full year sales were $19.6B, up 8% YoY.
    Biktarvy sales growth: 21% YoYBiktarvy U.S. market share: >50%Descovy sales growth: 21% YoYDescovy U.S. PrEP market share: >40%HIV treatment market growth: ~3% in 2024HIV prevention market growth: >16% YoY in Q4
    $5.5B16%7%
    Liver Disease
    Reflecting strong launch of Livdelzi in PBC and increased demand for HBV and HDV products, partially offset by lower HCV sales due to fewer patient starts. Sequentially, sales were down 2% primarily driven by lower HCV sales due to lower average realized price and timing of purchases. Full year sales were $3B, up 9% YoY.
    Livdelzi sales: $30M
    $719M4%-2%
    Oncology
    Reflecting growing presence in this area of high unmet need. Trodelvy year-over-year growth reflected higher demand in all regions. Cell therapy faced continued challenging competitive dynamics and slower-than-targeted uptake.
    Trodelvy sales: $355M (Q4)Trodelvy sales growth: 19% YoY (Q4)Trodelvy sales: $1.3B (FY24)Trodelvy sales growth: 24% YoY (FY24)Cell therapy sales: $488M (Q4)Cell therapy sales growth: 5% YoY (Q4)Cell therapy sales: $2B (FY24)Patients treated (Trodelvy & Cell Therapies): >80,000 to datePatients treated (Kite Cell Therapy): >7,000 in 2024
    $3.3B12%
    Veklury
    Primarily due to lower rates of COVID-19 hospitalizations and typical quarterly variability. Full year sales were $1.8B, down 18% from 2023.
    $337M-53%-51%

    Operational metrics

    13
    Total product sales ex-Veklury growth
    8%Exceeded 5-6% guidance
    FY24

    Well above the high end of guidance range.

    R&D expense
    $5.7BFlat with 2023
    FY24

    Non-GAAP basis. Reflects appropriate scale of investment to support diverse pipeline.

    SG&A expense
    $5.9BDown 3% from 2023
    FY24

    Non-GAAP basis. Q4 SG&A was $1.9B, up 16% from prior year.

    Non-GAAP Operating Margin
    30%
    FY24

    Reflects Q1 2024 acquisition of CymaBay. Q4 operating margin was 41%, up from 39% in Q4 2023.

    Quarterly cash dividend increase
    2.6%
    2025

    Committed to growing dividend over time.

    Share repurchases
    $1.2B
    FY24

    Used to offset equity dilution and additional opportunistic repurchases.

    Total capital returned to shareholders
    $5.1B
    FY24

    Priorities for capital allocation have not changed.

    Clinical programs
    54Up from 32 in 2019
    Current

    Reflects the most robust and diversified pipeline in Gilead's history.

    Revenue impact from Medicare Part D reform
    $1.1B
    2025

    Expected to mask robust demand-led volume growth in 2025.

    FX headwind on revenue
    $250M
    2025

    Due to U.S. dollar strengthening against major foreign currencies.

    Veklury revenue headwind
    $400MLower in 2025 vs 2024
    2025

    Additional growth headwind for 2025.

    Descovy PrEP coverage
    >85%
    Current

    Payers continue to recognize the benefits of PrEP.

    CAR T sites accreditation
    Current

    Working with industry groups and other manufacturers to address barriers through policy reform and exploring accreditation with groups like FACT to enable wider commercial reimbursement for cell therapies in large integrated community oncology practices.

    Industry KPIs

    8
    MetricValueDetails
    EPS$4.62USD
    Gross margin87%%
    Revenue net sales$28.6BUSD
    Effective tax rate19.2%%
    Pricing price realizationHigher average realized price
    Regulatory approvals filingsLenacapavir for HIV prevention
    Therapeutic drug market share>50%%
    Clinical trial efficacy safety dataAnito-cel ORR 97%, CR 62%, MRD negativity 93%%

    Product announcements

    2
    ProductTypeDetails
    Livdelzilaunch
    KITE-363launch

    Deals & partnerships

    4
    ArcellxCollaboration on anito-cel (BCMA CAR T therapy)

    Collaboration continues to yield promising results for anito-cel, targeting commercial launch in 2026.

    LEO PharmaAcquisition of STAT6 program~$250M

    The STAT6 program was added to Gilead's inflammation pipeline. The acquisition will be reflected in Q1 2025 results.

    CymaBayAcquisition of CymaBay$3.9B

    Acquisition occurred in Q1 2024, contributing to IPR&D expenses.

    TerrayCollaboration

    Related expenses were reflected in Q4 2024 acquired IPR&D.

    Risks & headwinds

    5
    Medicare Part D Reform2025

    Approximately $1.1 billion impact on 2025 revenue, with $900 million in HIV.

    Mitigation: Expects robust demand-led volume growth to continue, but it will be masked by the reform, effectively resetting the base for future growth.

    Veklury Sales DeclineQ4 2024, FY 2025

    Down 53% year-over-year in Q4 2024 to $337 million. Expected $400 million lower in 2025 versus 2024.

    Mitigation: Attributed to lower rates of COVID-19 hospitalizations. Guidance assumes a generally stable macro environment.

    Foreign Exchange (FX) Headwind2025

    $250 million headwind on 2025 revenue.

    Mitigation: Reflects the U.S. dollar strengthening against major foreign currencies. Guidance assumes FX at current rates.

    Cell Therapy Competitive Dynamics and Slower UptakeQ4 2024, 2025

    Cell therapy sales flat sequentially and up 5% year-over-year in Q4 2024.

    Mitigation: Working with industry groups and other manufacturers to address barriers through policy reform and exploring FACT accreditation to enable wider commercial reimbursement. Expects continued competitive headwinds in 2025.

    Q1 2025 HIV Revenue DeclineQ1 2025

    Expected to decline in the mid-teen percentage range quarter-over-quarter.

    Mitigation: Due to normal seasonal inventory drawdown and the IRA headwind.

    What to watch in Q1 FY25

    5

    Livdelzi European Commission decision

    Later this month
    CurrentPositive CHMP opinion received in December
    TargetFinal decision from European Commission

    Why it matters

    Determines market expansion for a new growth driver in the liver disease portfolio.

    Livdelzi also received a positive CHMP opinion in December, and we expect a final decision from the European Commission later this month.

    Q&A highlights

    7

    Will the new lenacapavir treatment options eventually replace Biktarvy, and how does this fit into the lifecycle management strategy before Biktarvy's LOE?

    Johanna Mercier explained that lenacapavir's long-acting options (daily, weekly, monthly, quarterly, twice-yearly) are designed to meet diverse patient needs and will likely erode some of Biktarvy's market share well before its LOE in late 2033, provided they meet Biktarvy's standard of care and offer long-acting administration.

    As long as it -- for us, it hits the standard of care that Biktarvy is set, plus brings optionality for patients with the long-acting administration.

    asked by Geoff Meacham · answered by Johanna Mercier

    2 min read6 chapters

    Detailed Narrative

    01

    HIV Franchise Strength and Future Outlook

    Gilead's HIV business demonstrated exceptional growth in FY24, with total sales up 8% to $19.6 billion, driven by Biktarvy's 13% growth and over 50% U.S. market share. The company anticipates continued volume growth, with lenacapavir for prevention expected to launch mid-2025, and a robust long-acting portfolio aiming for up to 7 new treatment and 2 prevention options by 2033. This strategy focuses on meeting diverse patient needs and evolving the standard of care beyond Biktarvy's current dominance.

    02

    Livdelzi's Strong Initial Launch

    Livdelzi, for primary biliary cholangitis (PBC), achieved $30 million in sales in its first full commercial quarter, exceeding internal expectations. Its differentiation in efficacy (ALP and pruritus) and safety is driving strong week-over-week growth, with European Commission approval expected soon following a positive CHMP opinion. The ongoing Phase III IDEAL trial is enrolling patients with partial UDCA response, potentially expanding the eligible patient population to an additional 20,000-25,000 patients in the U.S. and Europe.

    03

    Oncology Portfolio Expansion

    The oncology segment grew 12% to $3.3 billion in FY24, treating over 80,000 patients across its therapies. Trodelvy continues to gain adoption in metastatic breast cancer, with 6 ongoing Phase III trials and updates expected in 2025 for first-line metastatic triple-negative breast cancer (ASCENT-03 and ASCENT-04). The company is also initiating a Phase III trial for Trodelvy in extensive-stage small cell lung cancer in H1 2025, leveraging its FDA Breakthrough Therapy designation and promising Phase II data.

    04

    Cell Therapy Progress and Challenges

    Kite's cell therapy sales reached $2 billion in FY24, treating over 7,000 patients. While showing durable responses with Yescarta and Tecartus, the segment faces competitive headwinds and slower-than-targeted uptake. Anito-cel (BCMA CAR T) showed promising Phase II data with a 97% overall response rate and 62% complete response in multiple myeloma, targeting a 2026 launch. Gilead is actively working to address barriers to CAR T adoption in community oncology settings, including accreditation and policy reform.

    05

    Pipeline Depth and Innovation

    Gilead's pipeline has expanded to 54 clinical programs, up from 32 in 2019, reflecting a focus on innovation across HIV, oncology, and inflammation. Lenacapavir was recognized as Science's 2024 Breakthrough of the Year, highlighting its transformative potential. The company is also exploring CAR T in autoimmune diseases with KITE-363, demonstrating a commitment to addressing unmet medical needs beyond its traditional therapeutic areas.

    06

    Impact of Medicare Part D Reform and Other Headwinds

    The 2025 revenue guidance incorporates an approximate $1.1 billion impact from Medicare Part D reform, with $900 million affecting HIV sales. This reform, along with FX headwinds🌐 ($250 million) and lower Veklury sales ($400 million), is expected to mask underlying demand-led volume growth, particularly in HIV, for the upcoming year. Despite these challenges, management expects continued strong underlying demand and is focused on expense discipline to drive operating income growth.

    AI-generated summary of the company’s earnings call. Not investment advice.